AVTE Stock Overview
A clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Aerovate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.60 |
| 52 Week High | US$32.42 |
| 52 Week Low | US$1.25 |
| Beta | 1.01 |
| 1 Month Change | -2.99% |
| 3 Month Change | 26.21% |
| 1 Year Change | -88.97% |
| 3 Year Change | -76.77% |
| 5 Year Change | n/a |
| Change since IPO | -88.61% |
Recent News & Updates
Recent updates
Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely
Oct 01
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Jun 11Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
May 24Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 09We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate
Oct 17Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Jul 04Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 28A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jan 06Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Oct 14Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
Jul 01We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth
Jan 22Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Sep 30Shareholder Returns
| AVTE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | -3.3% | -0.4% |
| 1Y | -89.0% | -2.7% | 24.8% |
Return vs Industry: AVTE underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: AVTE underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| AVTE volatility | |
|---|---|
| AVTE Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVTE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVTE's weekly volatility has decreased from 17% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 51 | Tim Noyes | aerovatetx.com |
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc. Fundamentals Summary
| AVTE fundamental statistics | |
|---|---|
| Market cap | US$75.07m |
| Earnings (TTM) | -US$84.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs AVTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$84.61m |
| Earnings | -US$84.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVTE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:20 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aerovate Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vamil Divan | Guggenheim Securities, LLC |
| Eun Kyung Yang | Jefferies LLC |
| Yuchen Ding | Jefferies LLC |